Glutaric acidemia type 1 (GA1) is a rare inherited metabolic disorder caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase, which is involved in the metabolism of certain amino acids – lysine, tryptophan and hydroxyproline. This deficiency results in the accumulation of toxic metabolic by-products, which can manifest itself in a variety of clinical symptoms, including severe neurological impairment and metabolic crises. The disease usually first manifests in childhood, but its severity and clinical characteristics can vary from patient to patient.
History of the disease and interesting historical facts
Glutaric acidemia type 1 was first mentioned in the mid-20th century, when the disease became better known due to the efforts of researchers in the field of inherited metabolic disorders. In the 1970s, the main biochemical features of the disease were described, which made it possible to identify its genetic nature. Clinical cases studied by health care workers demonstrated high levels of glutaric acid in the urine and blood plasma of patients with these diseases. Over time, effective diagnostic methods have emerged, which has improved the understanding of the disease and approaches to its treatment.
Epidemiology
Glutaric acidemia type 1 is an extremely rare disorder, occurring with an incidence of approximately 1 in 40,000–100,000 live births. The disorder occurs in all ethnic groups, but prevalence data are not available in different populations. The incidence of the disorder itself may vary by region, level of awareness, and availability of diagnostic technologies. Some studies have noted that the incidence of GAA1 has increased with the introduction of neonatal screening programs.
Genetic predisposition to this disease
Glutaric acidemia type 1 is inherited in an autosomal recessive manner, meaning that two mutant alleles in the GCDH gene, which codes for the enzyme glutaryl-CoA dehydrogenase, are required for the disease to manifest. More than 50 different mutations have been identified in this gene, and most of them result in a complete or partial absence of enzyme activity. It is important to note that parents with one copy of the mutant gene may be healthy carriers, but they can pass the gene to their offspring, leading to the development of the disease.
Risk factors for the development of this disease
Risk factors for the development of glutaric acidemia type 1 include the following:
- Heredity. The presence of a sick child in the family increases the likelihood of the disease appearing in subsequent generations.
- Carriage of a mutation in the GCDH gene in parents.
- Problems with access to neonatal screening can make early diagnosis difficult.
- Lack of adequate genetic counseling for families with a history of metabolic disorders.
Diagnosis of this disease
Diagnosis of glutaric acidemia type 1 is based on a combination of clinical and laboratory methods. The main symptoms may include:
- Neurological disorders (seizures, hypotension, psychomotor retardation).
- Metabolic crises with vomiting, dehydration and psychomotor disintegration.
- Signs of metabolic acidemia (hyperventilation, weakness, change in level of consciousness).
Laboratory tests include:
- Urine analysis for the presence of glutaric acid and its derivatives.
- Blood biochemistry test to determine amino acid levels.
- Genetic testing to confirm mutation in the GCDH gene.
Radiological examinations may be used to evaluate neurological changes, and differential diagnosis includes other metabolic disorders such as homocystinuria and other diseases associated with amino acid metabolism disorders.
Treatment
General treatment of glutaric acidemia type 1 is aimed at preventing metabolic crises and correcting metabolic disorders. The main approaches include:
- A special diet with limited protein and added carbohydrates to reduce glutaric acid levels.
- Using oral medications such as L-carnitine to help remove excess toxins.
- Surgical procedures such as liver transplantation may be recommended in rare cases of severe disease.
- Other treatments may include gene therapy, which is being considered as a future possibility.
List of medications used to treat this disease
Medications used to treat glutaric acidemia type 1 include:
- L-carnitine.
- Coenzyme Q10.
- Special supplements of B vitamins.
Disease monitoring
Monitoring of a patient with glutaric acidemia type 1 includes:
- Regular blood and urine tests to monitor levels of glutaric acid and other metabolites.
- Assessment of neurological status to identify possible complications.
- The prognosis of the disease varies and depends on the age at which treatment begins and the strictness of the diet.
- Complications may include neurological deficits and psychomotor retardation.
Age-related features of the disease
Glutaric acidemia type 1 varies in clinical manifestations depending on age. Neonates have more pronounced metabolic crises and neurological disorders. Older children may develop psychomotor retardation and cognitive impairment. Adult patients may sometimes have milder symptoms, but prolonged instability may lead to neuropsychiatric disorders.
Questions and Answers
- What are the main symptoms of glutaric acidemia type 1? The main symptoms are convulsions, hypotension, delayed psychomotor development, metabolic crises with vomiting and dehydration.
- How is glutaric acidemia type 1 diagnosed? Diagnosis includes urine tests for glutaric acid, blood chemistry tests, and genetic testing for mutations in the GCDH gene.
- How is this disease treated? Treatment includes a special diet, L-carnitine and, in rare cases, surgery.
- What is the clinical course of the disease in children and adults? Newborns may experience more severe manifestations, while adults may have less severe symptoms, but serious long-term consequences are also possible.
- What are the complications of glutaric acidemia type 1? Complications include neurological deficits, psychomotor delay, and metabolic crises that can be life-threatening.
Advice from Dr. Oleg Korzhikov
“Glutaric acidemia type 1 requires careful monitoring and early diagnosis. Parents with a family history of the disorder should be aware of the risks and undergo genetic testing. Supportive diet and monitoring by a pediatrician and metabolic specialist can help avoid serious complications. Emphasis on education and communication with doctors will ensure proper care for your child. Remember, early referral to a specialist at the first signs can save lives.”
